Welcome to our dedicated page for 10X Genomics SEC filings (Ticker: TXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
10x Genomics, Inc. filings document regulatory disclosures for a Nasdaq-listed life science technology company with Class A common stock. Form 8-K reports furnish quarterly and annual operating results, selected preliminary results and business updates related to single cell and spatial biology platforms, including instruments, consumables, software and product launches.
The filing record also includes definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items, as well as Form 8-K disclosure for executive officer transitions and related compensation arrangements. These documents describe TXG's public-company governance, registered security, financial reporting events and material corporate updates.
10x Genomics, Inc. Chief Executive Officer Serge Saxonov reported open‑market sales of Class A Common Stock primarily tied to tax withholding on equity awards. On May 26, 2026, he sold 10,718 shares at a weighted average price of $24.7092 per share. On May 22, 2026, he sold 18,175 shares at a weighted average price of $24.4415 per share. A footnote states the shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units and that the transactions were effected under his Rule 10b5‑1 trading plan adopted on November 29, 2025. After these transactions, Saxonov directly holds 1,138,380 shares, with additional indirect holdings through the Andromeda Trust, Y/S Descendants' Trust, and Y/S Pot Trust, for which he serves as trustee.
10x Genomics, Inc. director and officer Benjamin J. Hindson reported a small share disposition tied to tax obligations. On May 22, 2026, he sold 11,595 shares of Class A Common Stock at $24.4415 per share to cover tax withholding from vesting restricted stock units. Following this transaction, he still directly holds 502,000 shares, indicating the move is a routine, compensation-related tax event rather than a large discretionary sale.
10x Genomics, Inc. Chief Financial Officer Adam Taich reported a sale of company stock primarily to satisfy taxes from equity compensation. On May 22, 2026, he sold 15,098 shares of Class A Common Stock at an average price of $24.4415 per share. According to the footnote, the shares were sold to cover tax withholding obligations related to the vesting of restricted stock units, making this a routine, compensation-driven transaction rather than a discretionary portfolio move. After the sale, Taich directly holds 379,898 shares of 10x Genomics Class A Common Stock.
TXG Genomics insider Serge Saxonov filed a Form 144 disclosing proposed sales of Class A Common shares. The notice lists multiple recently vested RSU lots and an option exercise as the source of shares, and shows four dispositions in Mar–Apr 2026 with specific share counts and proceeds.
Serge Saxonov reported proposed and recent sales of Common Stock via a Form 144 notice and an RSU grant. The filing lists a Restricted Stock Unit grant of 35,270 shares dated 05/21/2026 (services rendered) and multiple open-market sales in 2026, including transactions on 02/23/2026, 03/02/2026, 03/23/2026, 03/24/2026, and 04/14/2026. The document reflects routine insider sales activity and a compensation-related equity grant.
The issuer filed a Form 144 disclosing intended sales of Common Stock related to a Restricted Stock Unit grant of 26,276 shares dated 05/21/2026. The filing also records a prior sale of 7,826 shares on 02/23/2026 for $145,378.91.
Adam Taich filed a Form 144 to sell 32,648 shares of Common Stock. The filing lists the proposed sale as arising from a Restricted Stock Unit Grant dated 05/21/2026. The notice also reports a prior sale of 8,968 shares on 02/23/2026 for $166,593.16.
10x Genomics, Inc. reported Q1 2026 revenue of $150.8 million, slightly below $154.9 million a year earlier as prior-year license and royalty revenue tied to a Vizgen settlement rolled off. Core products and services revenue rose to $149.9 million, up 9% year over year, driven by 13% growth in consumables.
Gross profit was $106.2 million with gross margin improving to 70% from 68%, helped by lower inventory write-downs and warranty costs, partly offset by lower license revenue. Operating expenses fell 15% to $123.2 million, reflecting lower legal, personnel and marketing costs.
Net loss narrowed to $13.5 million (basic and diluted loss per share $0.10) from $34.4 million. The company generated $26.1 million of operating cash flow and ended the quarter with $539.8 million in cash, cash equivalents and marketable securities, while continuing to fund litigation, integration of the Scale Biosciences acquisition and milestone and lease commitments.
10x Genomics reported first quarter 2026 results with modest revenue pressure but improved profitability. Revenue was $150.8 million, down 3% from the prior-year quarter, but up 9% when excluding $16.8 million of one-time license and royalty revenue recognized in the first quarter of 2025 related to patent litigation settlements.
Gross margin improved to 70% from 68%, helped by lower warranty costs and inventory write-downs and partially offset by lower license and royalty revenue. Operating expenses fell 15% to $123.2 million from $144.8 million, mainly due to lower outside legal and personnel expenses, leading to a narrower operating loss of $17.0 million versus $39.3 million a year earlier. Net loss improved to $13.5 million from $34.4 million.
The company ended March 31, 2026 with $539.8 million in cash, cash equivalents and marketable securities. It maintained full-year 2026 revenue guidance of $600 million to $625 million, which represents 0% to 4% growth over 2025 when excluding non-recurring 2025 license and royalty revenue. 10x also launched its new Atera spatial platform and announced the STELA spatial data initiative in partnership with Bioptimus.
Vanguard Capital Management reports beneficial ownership of 6,166,597 shares of 10X Genomics Inc Common Stock, representing 5.24% of the class. The filing states Vanguard has sole dispositive power over 6,166,597 shares and sole voting power over 897,011 shares. The disclosure notes these holdings reflect interests managed by Vanguard Capital Management LLC and specified affiliate business divisions.